These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
131 related articles for article (PubMed ID: 4424774)
41. Immunomodulation of host resistance by tumor variants. Fuji H Transplant Proc; 1984 Apr; 16(2):460-2. PubMed ID: 6609454 [TBL] [Abstract][Full Text] [Related]
42. Combination of dihydroxyanthraquinone and radiation on L1210 murine leukemia. Kimler BF; Hacker MP Cancer Clin Trials; 1981; 4(2):173-6. PubMed ID: 7249253 [TBL] [Abstract][Full Text] [Related]
43. Optimum time sequence for the administration of vincristine and cyclophosphamide in vivo. Razek A; Vietti T; Valeriote F Cancer Res; 1974 Aug; 34(8):1857-61. PubMed ID: 4842737 [No Abstract] [Full Text] [Related]
44. Comparison of in vitro and in vivo effects of thymidine on L1210 leukemia in mice. Zaharko DS; Ramonas LM J Natl Cancer Inst; 1982 May; 68(5):875-80. PubMed ID: 6951095 [TBL] [Abstract][Full Text] [Related]
45. Tolerance and contact sensitivity to DNFB in mice. 3. Transfer of tolerance with "suppressor T cells". Phanupak P; Moorhead JW; Claman HN J Immunol; 1974 Oct; 113(4):1230-6. PubMed ID: 4547338 [No Abstract] [Full Text] [Related]
46. Recovery from a viral respiratory infection. II. Passive transfer of immune spleen cells to mice with influenza pneumonia. Wells MA; Ennis FA; Albrecht P J Immunol; 1981 Mar; 126(3):1042-6. PubMed ID: 7462625 [No Abstract] [Full Text] [Related]
47. 6-Mercaptopurine-induced potentiation of active immunotherapy in L1210-bearing mice treated with concanavalin A-bound leukemia cell vaccine. Kataoka T; Akahori Y; Sakurai Y Cancer Res; 1984 Feb; 44(2):519-24. PubMed ID: 6537896 [TBL] [Abstract][Full Text] [Related]
52. Prolonged remissions of lymphatic leukemia in DBA-2 mice induced with endogenously produced lactate dehydrogenase antibody. Lakatos G; Strefling A; Joseph RR; McCann DS Cancer Res; 1974 Jun; 34(6):1395-400. PubMed ID: 4207862 [No Abstract] [Full Text] [Related]
53. Immunotherapy in Friend virus leukemia. II. Prevention of friend leukemia by passive administration of immune serum and cells to young mice. Wahren B J Natl Cancer Inst; 1968 Oct; 41(4):931-8. PubMed ID: 5693664 [No Abstract] [Full Text] [Related]
54. Adoptive therapy of established syngeneic leukemia by cells primarily sensitized in vitro. Cheever MA; Greenberg PD; Fefer A Cancer Res; 1981 Jul; 41(7):2658-63. PubMed ID: 7018668 [TBL] [Abstract][Full Text] [Related]
55. Differential tumor immunogenicity of DBA/2 mouse lymphoma L1210 and its sublines. III. Control of host resistance to drug-resistant L1210 sublines by H-2-linked and non-H-2-linked genes. Fuji H; Murakami M J Natl Cancer Inst; 1983 Jan; 70(1):119-25. PubMed ID: 6296515 [TBL] [Abstract][Full Text] [Related]
56. Induction of delayed-type hypersensitivity by ICRC anti-leprosy vaccine and the adoptive transfer of cell-mediated immunity in mice. Jeevan A; Bapat CV Indian J Lepr; 1984; 56(4):754-63. PubMed ID: 6398339 [TBL] [Abstract][Full Text] [Related]
59. The response of C3H mice to an L1210 tumor allograft. Nevalainen DE Res Commun Chem Pathol Pharmacol; 1974 Apr; 7(4):771-4. PubMed ID: 4828768 [No Abstract] [Full Text] [Related]
60. Characterization of a monoclonal antibody to L1210 leukaemia. Testorelli C; Morelli S; Goldin A; Nicolin A Br J Cancer; 1982 Mar; 45(3):395-402. PubMed ID: 7073934 [TBL] [Abstract][Full Text] [Related] [Previous] [Next] [New Search]